Healthcare


 Biome Australia's Record-Breaking FY25: Revenue Surges Amid Growing Demand

Biome Australia's Record-Breaking FY25: Revenue Surges Amid Growing Demand

July 09, 2025 05:16 PM AEST| By Team Kalkine Media

Highlights,Biome Australia reports record FY25 revenue milestone,Quarterly and monthly sales performance at all-time highs,Strong momentum driven by consistent demand for health products,Biome Australia (ASX:BIO) has released a notable update to the...

 Island Pharmaceuticals Fast-Tracks Galidesivir Acquisition to Advance Anti-Viral Pipeline

Island Pharmaceuticals Fast-Tracks Galidesivir Acquisition to Advance Anti-Viral Pipeline

July 09, 2025 04:40 PM AEST| By Team Kalkine Media

Highlights,Island Pharmaceuticals accelerates galidesivir program acquisition,Strategic focus on Marburg virus treatment development,Priority review voucher offers future regulatory advantage,Island Pharmaceuticals (ASX:ILA),has announced the acceler...

 Summerset Group (ASX:SNZ) Supports Rebound in ASX 200 Healthcare Sector

Summerset Group (ASX:SNZ) Supports Rebound in ASX 200 Healthcare Sector

July 09, 2025 04:37 PM AEST| By Team Kalkine Media

Highlights,Summerset Group posts record-breaking Q2 growth,Housing recovery and strong offerings drive sustained momentum,Sector sentiment lifted as ASX 200 shows signs of revival,Summerset Group Holdings Ltd (ASX:SNZ), a dual-listed retirement villa...

 Prescient Therapeutics Advances PTX-100 to Phase 2 in Fight Against T-Cell Lymphoma

Prescient Therapeutics Advances PTX-100 to Phase 2 in Fight Against T-Cell Lymphoma

July 09, 2025 02:45 PM AEST| By Team Kalkine Media

Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma,Analysts lift valuation outlook on clinical potential and market size,Prescient expands pipeline with innovative CAR-T platforms,Prescient Therapeutics (ASX...

 PTX-100 Phase 2 Trial Advances Prescient Therapeutics (ASX:PTX) in All Ordinaries Spotlight

PTX-100 Phase 2 Trial Advances Prescient Therapeutics (ASX:PTX) in All Ordinaries Spotlight

July 09, 2025 02:27 PM AEST| By Team Kalkine Media

Highlights,Prescient Therapeutics initiates Phase 2 trial for PTX-100 targeting T-Cell Lymphoma,PTX-100 shows activity in patients with limited treatment options,CAR-T platforms CellPryme and OmniCAR add to company’s oncology portfolio,Prescient Ther...

 Orthocell's Record-Breaking FY2025 Signals Bold Momentum Beyond Borders

Orthocell's Record-Breaking FY2025 Signals Bold Momentum Beyond Borders

July 09, 2025 01:53 PM AEST| By Team Kalkine Media

Highlights,Orthocell hits record FY2025 revenue milestone,Expansion into the US gains significant traction,Strategic international regulatory approvals fuel growth,Orthocell (ASX:OCC) has delivered an impressive financial performance for FY2025, achi...

 Proteomics International (ASX:PIQ) Shows Signs of Recovery After Challenging Year

Proteomics International (ASX:PIQ) Shows Signs of Recovery After Challenging Year

July 09, 2025 10:03 AM AEST| By Team Kalkine Media

Highlights,Weekly rebound sparks interest in PIQ,Long-term holders still face deep losses,Revenue growth continues despite setbacks,Proteomics International Laboratories (ASX:PIQ) experienced a notable lift in its share price over the past week, brin...

 Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues

Nova Eye Medical (ASX:EYE) Surges Ahead with Record FY25 Revenues

July 08, 2025 06:25 PM AEST| By Team Kalkine Media

Highlights,Nova Eye Medical reports record FY25 revenue performance,Significant uplift in US market sales drives growth,H2FY25 shows strong momentum across operations,Nova Eye Medical (ASX:EYE) has released its full-year financial results for FY25, s...

 Cannabinoid Therapy Steps Up in Slovenia: Argent BioPharma (ASX:RGT) Expands Epilepsy Treatment Reach

Cannabinoid Therapy Steps Up in Slovenia: Argent BioPharma (ASX:RGT) Expands Epilepsy Treatment Reach

July 08, 2025 06:15 PM AEST| By Team Kalkine Media

Highlights,Argent BioPharma expands cannabinoid epilepsy treatment in Slovenia,Successful pilot leads to routine hospital use,Multi-year regulatory collaboration drives clinical adoption,Argent BioPharma (ASX:RGT) has taken a significant step forward...

 Sofdra™ Gains Traction: Botanix Pharmaceuticals (ASX:BOT) Reports Positive Growth Momentum

Sofdra™ Gains Traction: Botanix Pharmaceuticals (ASX:BOT) Reports Positive Growth Momentum

July 08, 2025 05:53 PM AEST| By Team Kalkine Media

Highlights,Sofdra™ shows steady monthly growth post-launch,Over 16,000 prescriptions filled since February,Expansion into new sales territories underway,Botanix Pharmaceuticals (ASX:BOT) has unveiled strong early-stage performance metrics for its der...

 PME’s Growth Momentum: Key Insights into This ASX 100 Radiology Software Leader

PME’s Growth Momentum: Key Insights into This ASX 100 Radiology Software Leader

July 08, 2025 05:43 PM AEST| By Team Kalkine Media

Highlights,Pro Medicus demonstrates robust profit and revenue growth,Strong balance sheet supports operational resilience,Return on equity reflects high capital efficiency,Pro Medicus (ASX:PME), a prominent medical imaging software provider, has made...

 Monash IVF (ASX:MVF) Attracts Market Buzz Despite Recent Setback

Monash IVF (ASX:MVF) Attracts Market Buzz Despite Recent Setback

July 08, 2025 04:49 PM AEST| By Team Kalkine Media

Highlights,Monash IVF (MVF) under focus after operational mishap,Adjusted financial outlook reflects anticipated market share shifts,Sector valuation hints at consolidation prospects,Monash IVF (ASX:MVF), a prominent name in Australia’s fertility ser...

 CSL (ASX:CSL) Share Price Under Watch: Exploring the Resilience of a Leading Healthcare Stock in the ASX 300 Index

CSL (ASX:CSL) Share Price Under Watch: Exploring the Resilience of a Leading Healthcare Stock in the ASX 300 Index

July 07, 2025 06:29 PM AEST| By Team Kalkine Media

Highlights,CSL operates across plasma, flu vaccine, and renal care segments,Part of the ASX 300 Index, reflecting its position among Australia’s largest listed entities,Healthcare demand continues to show global momentum,CSL Ltd (ASX:CSL) remains a p...

 Nanosonics (ASX:NAN) Elevates Infection Prevention with trophon3 Launch

Nanosonics (ASX:NAN) Elevates Infection Prevention with trophon3 Launch

July 07, 2025 04:46 PM AEST| By Team Kalkine Media

Highlights,Nanosonics unveils trophon3 with faster disinfection and digital integration,trophon2 Plus software upgrade brings advanced features to existing systems,Launch extends across multiple regions; FDA review in progress,Nanosonics (ASX:NAN), a...

 CSL Ltd (ASX:CSL) Strengthens Healthcare Footprint in ASX Top 300

CSL Ltd (ASX:CSL) Strengthens Healthcare Footprint in ASX Top 300

July 04, 2025 07:41 PM AEST| By Team Kalkine Media

Highlights,CSL Ltd is a key healthcare company in the ASX Top 300 and ASX 100,Business operations include plasma therapies, flu vaccines, and kidney treatments,Regular payouts place CSL under asx dividend stocks,CSL Ltd (ASX:CSL) is listed under the,...

 Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption

Orthocell's Remplir Drives Record Quarterly Revenue Surge on Expanding Hospital Adoption

July 04, 2025 03:13 PM AEST| By Team Kalkine Media

Highlights,Record A$2.73 million quarterly revenue,Over 206 surgeons now using Remplir in 166+ hospitals,US expansion set to accelerate future momentum,Orthocell Ltd (ASX:OCC) has reported a record-breaking revenue performance for the June 2025 quart...

 ASX 200 Health Sector Lags but Amplia and Biotech Peers Shine in June

ASX 200 Health Sector Lags but Amplia and Biotech Peers Shine in June

July 04, 2025 02:16 PM AEST| By Team Kalkine Media

Highlights,ASX 200 Health Care sector underperforms broader index despite isolated stock rallies,Amplia Therapeutics records complete cancer responses in ACCENT trial,Neuro and radiopharma companies advance on clinical updates and acquisitions,The,AS...

 Imugene Advances Cancer Trials with Fresh Funding and Clinical Progress

Imugene Advances Cancer Trials with Fresh Funding and Clinical Progress

July 04, 2025 02:14 PM AEST| By Team Kalkine Media

Highlights,Imugene receives A$5.87M in R&D tax refund for 2024.,Initiates Phase II dosing for colorectal cancer therapy.,Secures key US patent for onCARlytics platform,Imugene Ltd (ASX:IMU) has taken notable strides in advancing its immuno-oncology p...

 CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs

CSL and Endeavour Shine as Value Picks in ASX 100 Near Highs

July 04, 2025 01:25 PM AEST| By Team Kalkine Media

Highlights,CSL Ltd remains focused on growth despite ongoing share price pressure,Endeavour Group continues to maintain market presence through retail network strength,Both companies are listed on the,ASX 100,and trade below recent highs,With the,S&P...

 ASX 300: PTX-100 Advances in Clinical Trials as Prescient Therapeutics Strengthens Biotech Footprint

ASX 300: PTX-100 Advances in Clinical Trials as Prescient Therapeutics Strengthens Biotech Footprint

July 04, 2025 01:21 PM AEST| By Team Kalkine Media

Highlights,Prescient Therapeutics progresses PTX-100 into Phase 2a trials following favourable outcomes in early-stage testing,The company receives US FDA orphan drug and fast track designations for CTCL treatment,PTX-100 shows encouraging tolerance...

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.